Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 13/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464982 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL2294321 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111704 | 0.94 | ADORA2A (0.88) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111713 | 0.94 | ADORA2A (0.88) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111385 | 0.93 | ADORA2A (0.86) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111379 | 0.93 | ADORA2A (0.86) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL23898701 | 0.92 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL7757379 | 0.92 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL2296477 | 0.92 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL13010610 | 0.92 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | claimed |
| WO-2009076580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2009-06-18 | — | — | WO | claimed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| EP-0515514-B1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | DISCOVERY THERAPEUTICS INC (US) | 2000-08-30 | — | — | EP | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| US-RE36494-E | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents | DISCOVERY THERAPEUTICS, INC. (US) | 2000-01-11 | — | — | US | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0515514-A4 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | — | 1993-01-13 | — | — | EP | claimed |
| EP-0515514-A1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | WHITBY RESEARCH, Inc. (US) | 1992-12-02 | — | — | EP | claimed |
| US-5140015-A | Racemic mixture for inducing an adenosine response in humans and animals | WHITBY RESEARCH, INC. (US) | 1992-08-18 | — | — | US | claimed |
| WO-1991013082-A1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | WHITBY RESEARCH, INC. (US) | 1991-09-05 | — | — | WO | claimed |
| US-9414901-B2 | Drug-eluting stents for adenosine receptor modulation | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | disclosed |
| US-5140015-A | Racemic mixture for inducing an adenosine response in humans and animals | WHITBY RESEARCH, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1991013082-A1 | 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS | WHITBY RESEARCH, INC. (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.